View Item 

Show simple item record

Handling Worker and Third‐Party Exposures to Nanotherapeutics During Clinical Trials
dc.contributor.authorRamachandran, Gurumurthyen_US
dc.contributor.authorHoward, Johnen_US
dc.contributor.authorMaynard, Andrewen_US
dc.contributor.authorPhilbert, Martinen_US
dc.date.accessioned2013-02-12T19:00:36Z
dc.date.available2014-02-03T16:21:43Zen_US
dc.date.issued2012-12en_US
dc.identifier.citationRamachandran, Gurumurthy; Howard, John; Maynard, Andrew; Philbert, Martin (2012). "Handling Worker and Third‐Party Exposures to Nanotherapeutics During Clinical Trials." The Journal of Law, Medicine & Ethics 40(4). <http://hdl.handle.net/2027.42/96288>en_US
dc.identifier.issn1073-1105en_US
dc.identifier.issn1748-720Xen_US
dc.identifier.urihttps://hdl.handle.net/2027.42/96288
dc.publisherBlackwell Publishing Ltden_US
dc.publisherWiley Periodicals, Inc.en_US
dc.titleHandling Worker and Third‐Party Exposures to Nanotherapeutics During Clinical Trialsen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelLaw and Legal Studiesen_US
dc.subject.hlbsecondlevelMedicine (General)
dc.subject.hlbtoplevelGovernment, Politics and Lawen_US
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDean of the School of Public Health and a Professor of Toxicology at the University of Michigan.en_US
dc.contributor.affiliationumDirector of the Risk Science Center; the Charles and Rita Gelman Risk Science Professor; and a Professor Environmental Health Sciences at the School of Public Health at the University of Michigan.en_US
dc.contributor.affiliationotherDirector of the National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services.en_US
dc.contributor.affiliationotherProfessor in the Division of Environmental Health Sciences at the School of Public Health at the University of Minnesota in Minneapolis, MN.en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/96288/1/j.1748-720X.2012.00714.x.pdf
dc.identifier.doi10.1111/j.1748-720X.2012.00714.xen_US
dc.identifier.sourceThe Journal of Law, Medicine & Ethicsen_US
dc.identifier.citedreferenceSee Murashov, supra note 8.en_US
dc.identifier.citedreferenceId.en_US
dc.identifier.citedreferenceR. Kocher and N. R. Sahni, “Rethinking Health Care Labor,” New England Journal of Medicine 365 ( 2012 ): 1370 – 1372.en_US
dc.identifier.citedreferenceU.S. Dept. of Labor (US DOL), Career Guide to Industries, “Health Care,” Bureau of Labor Statistics, 2006–2007 edition), at pp 231, < http://www.bls.gov/oco/cg/cgs035.htm > (last visited November 28, 2012)en_US
dc.identifier.citedreferenceJ. Lipscomb and B. Borwegen, “Health Care Workers,” in B. S. Levy and D. H. Wegman, eds., Occupational Health: Recognizing and Preventing Work‐Related Disease and Injury, 4th ed. ( Philadelphia: Lipppincott Williams & Wilkins, 2000 ): at 767–778; Centers for Disease Control (CDC), “Overview: Risks and Prevention of Sharps Injuries in Healthcare Personnel,” in Workbook for Designing, Implementing, and Evaluating a Sharps Injury Prevention Program,” available at < http://www.cdc.gov/sharpssafety/ > (last visited November 28, 2012).en_US
dc.identifier.citedreferenceCenters for Disease Control and Prevention & National Institutes of Health (CDC/NIH), Biosafety in Microbiological and Biomedical Laboratories: Centers for Disease Control and Prevention, 5th ed., 2009, National Institutes of Health, available at < http://www.cdc.gov/biosafety/publications/bmbl5/BMBL.pdf > (last visited November 28, 2012).en_US
dc.identifier.citedreferenceSee NIOSH, supra note 16.en_US
dc.identifier.citedreferenceNational Institute for Occupational Safety and Health (NIOSH), Preventing Occupational Exposure to Antineoplastic and other Hazardous Drugs in Health Care Settings, 2004, available at < http://www.cdc.gov/niosh/docs/2004‐165/pdfs/2004‐165sum.pdf > (last visited November 28, 2012).en_US
dc.identifier.citedreferenceSee NIOSH, supra note 16; National Institute for Occupational Safety and Health (NIOSH), Workplace Solutions: Medical Surveillance for Health Care Workers Exposed to Hazardous Drugs, DHHS (NIOSH) Publication Number 2007–117 (2007); National Institute for Occupational Safety and Health (NIOSH), Workplace Solutions: Personal Protective Equipment for Health Care Workers Who Work with Hazardous Drugs, DHHS (NIOSH) Publication No. 2009–106 (2009); National Institute for Occupational Safety and Health (NIOSH), NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, DHHS (NIOSH) Publication Number 2010–167 (2010).en_US
dc.identifier.citedreferenceB. D. Naumann, E. V. Sargent, B. S. Starkman, W. J. Fraser, G. T. Becker, and G. D. Kirk, “Performance‐Based Exposure Control Limits for Pharmaceutically Active Ingredients,” American Industrial Hygiene Association Journal 57 ( 1996 ): 33 – 42; World Health Organization (WHO), Quality Assurance of Pharmaceuticals: A Compendium of Guidelines and Related Materials, vol. 2 (including updates), Good Manufacturing Practices and Inspection, updated ed., Geneva, WHO, 2004, available at < http://whqlibdoc.who.int/publications/2004/9241546190.pdf > (last visited November 28, 2012).en_US
dc.identifier.citedreferenceSee NIOSH, supra note 50.en_US
dc.identifier.citedreferenceSee Murashov, supra note 8.en_US
dc.identifier.citedreferenceL. Amass, W. Ling, T. E. Freese, C. Reiber, J. J. Annon, A. J. Cohen, D. McCarty, M. S. Reid, L. S. Brown, C. Clark, D. M. Ziedonis, J. Krejci, S. Stine, T. Winhusen, G. Brigham, D. Babcock, J. A. Muir, B. J. Buchan, and T. Horton, “Bringing Buprenorphine‐Naloxone Detoxification to Community Treatment Providers: The NIDA Clinical Trials Network Field Experience,” American Journal on Addictions 13 ( 2004 ): S42 – S66; F. Wood, H. Prout, A. Acharjya, J. Nuttall, K. Hood, and C. Butler, “Exploring the Ethical and Practical Challenges of Conducting Clinical Trials in Care Home Settings,” Trials 12, Supp. 1 (2011): A38; P. Abernethy, L. S. Schwartzberg, D. Li, D. Scott, and M. Hensley, “Feasibility of Conducting Home‐based Clinical Trials in Patients with Advanced Pancreatic Cancer,” Journal of Clinical Oncology 28, no. 15 (2010): May 20 Supplement, Abstract e14647; C. M. Sackley, C. J. Atkinson, and M. F. Walker, “Occupational Therapy in Nursing and Residential Care Settings: A Description of a Randomised Controlled Trial Intervention,” British Journal of Occupational Therapy 67, no. 3 (2004): 104–110; G. M. Lucas, C. W. Flexner, and R. D. Moore, “Directly Administered Antiretroviral Therapy in the Treatment of HIV Infection: Benefit or Burden?” AIDS Patient Care and STDs 16, no. 11 (2002): 527–535; J. S. Eisch, J. Colling, J. Ouslander, B. J. Hadley, and E. Campbell, “Issues in Implementing Clinical Research in Nursing Home Settings,” Journal of the New York State Nurses Association 22, no. 3 (1991): 18–22.en_US
dc.identifier.citedreferenceSee US DOL, supra note 45.en_US
dc.identifier.citedreferenceK. Henriksen, A. Joseph, T. Zayas‐Cabán, “The Human Factors of Home Health Care: A Conceptual Model for Examining Safety and Quality Concerns,” Journal of Patient Safety 5, no.4 ( 2009 ): 229 – 236.en_US
dc.identifier.citedreferenceA. Myers, R. C. Jensen, D. Nestor, and J. Rattiner, “Low Back Injuries among Home Health Aides Compared with Hospital Nursing Aides,” Home Health Care Service Quarterly 14 ( 1993 ): 149 – 155.en_US
dc.identifier.citedreferenceR. Gershon, M. Pogorzelska, K. Qureshi, and M. Sherman, “Home Health Care Registered Nurses and the Risk of Percutaneous Injuries: A Pilot Study,” American Journal of Infection Control 36 ( 2008 ): 165 – 172; L. E. Danzig, L. J. Short, K. Collins, M. Mahoney, S. Sepe, L. Bland, and W. R. Jarvis “Bloodstream Infection Associated with Needleless Intravenous Infusion System in Patients Receiving Home Infusion Therapy,” Journal of the American Medical Association 273 (1995): 1862–1864; A. N. Do, B. J. Ray, S. Banerjee, A. F. Ilian, B. J. Barnett, M. H. Pham, K. A. Hendricks, and W. R. Jarvis, “Bloodstream Infection Associated with Needleless Device Use and the Importance of Infection‐Control Practices in the Home Health Care Setting,” Journal of Infectious Diseases 179 (1999): 442–448.en_US
dc.identifier.citedreferenceSee Gershon, supra note 69.en_US
dc.identifier.citedreferenceSee NIOSH, supra note 54.en_US
dc.identifier.citedreferenceSee Gershon, supra note 69.en_US
dc.identifier.citedreferenceNational Federation of Independent Business, “State by State Comparison of Worker's Compensation Laws,” available at < http://www.nfib.com/legal‐center/compliance‐resource‐center/compliance‐resource‐item/cmsid/57181 > (last visited November 28, 2012).en_US
dc.identifier.citedreferenceD. Thassu, M. Deleers, and Y. Pathak, Nanoparticulate Drug Delivery Systems ( Informa Healthcare: New York, London, 2007.en_US
dc.identifier.citedreferenceP. Boisseau and B. Loubaton “Nanomedicine, Nanotechnology in Medicine,” Comptes Rendus Physique 12, no. 7, ( 2011 ): 620 – 636.en_US
dc.identifier.citedreferenceA. N. Moran, “Nanomedicine Lacks Recognition In Europe,” Nature Biotechnology 24, no. 2 ( 2006 ): 121.en_US
dc.identifier.citedreferenceB. Kelly, “Nanomedicines: Regulatory Challenges and Risks Ahead,” 2010, at 14 – 17 available at < http://www.cov.com/files/Publication/8dc7cd17‐d1f6‐4290‐ac47‐2fde70df9c3b/Presentation/PublicationAttachment/e72f62ed‐f181‐47cd‐985a‐31fdd57d5bea/Nanomedicines%20Regulatory%20Challenges%20and%20Risks%20Ahead.pdf > (last visited November 28, 2012).en_US
dc.identifier.citedreferenceSee Boisseau and Loubaton, supra note 2.en_US
dc.identifier.citedreferenceSee Thassu et al., supra note 1; Boisseau and Loubaton, supra note 2; V. Murashov, “Occupational Exposure to Nanomedical Applications,” Nanomedicine and Nanobiotechnology 1, no. 2 (2009): 203–213.en_US
dc.identifier.citedreferenceR. Singh, D. Pantarotto, L. Lacerda, G. Pastorin, C. Klumpp, M. Prato, A. Bianco, and K. Kostarelos, “Tissue Biodistribution and Blood Clearance Rates of Intravenously Administered Carbon Nanotube Radiotracers,” Proceedings of the National Academy of Sciences 103, no. 9 ( 2006 ): 3357 – 3362.en_US
dc.identifier.citedreferenceNational Science and Technology Council Committee on Technology Subcommittee on Nanoscale Science, and Technology (NSET), National Nanotechnology Initiative: Strategic Plan, Washington, D.C., 2011, available at < http://www.nano.gov/node/581 > (last visited November 28, 2012).en_US
dc.identifier.citedreferenceM. Roco, O. Renn, and A. Jäger, “Nanotechnology Risk Governance,” in M. Roco, O. Renn, A. Jäger, eds., Global Risk Governance ( The Netherlands: Springer, 2008 ): 301 – 27, available at < http://www.springerlink.com/content/j102352637435844/ > (last visited November 28, 2012).en_US
dc.identifier.citedreferenceM. Auffan, J. Rose, J.Y. Bottero, G. V. Lowry, J. P. Jolivet, and M. R. Wiesner, “Towards a Definition of Inorganic Nanoparticles from an Environmental, Health and Safety Perspective,” Nature Nanotechnology 4, no. 10 ( 2009 ): 634 – 641.en_US
dc.identifier.citedreferenceM. Ferrari, “Cancer Nanotechnology: Opportunities and Challenges,” Nature Reviews Cancer 5, no. 3 ( 2005 ): 161 – 171, abstract available at < http://www.ncbi.nlm.nih.gov/pubmed/15738981 > (last visited November 28, 2012).en_US
dc.identifier.citedreferenceCenter for Drug Evaluation and Research (CDER), Office of Pharmaceutical Science, Reporting Format for Nanotechnology‐Related Information in CMC Review, June 2010, available at < http://www.fda.gov/downloads/AboutFDA/CentersOffices/.../UCM214304.pdf > (last visited November 28, 2012).en_US
dc.identifier.citedreferenceOccupational Safety and Health Administration (OSHA), “Safety and Health Tips: Nanotechnology,” available at < http://www.osha.gov/dsg/nanotechnology/nanotechnology.html > (last visited November 28, 2012).en_US
dc.identifier.citedreferenceNational Institute for Occupational Safety and Health (NIOSH), Approaches to Safe Nanotechnology: Managing the Health and Safety Concerns Associated with Engineered Nanomaterials ( 2009 ), available at < http://www.cdc.gov/niosh/docs/2009‐125/pdfs/2009‐125.pdf > (last visited November 28, 2012).en_US
dc.identifier.citedreferenceA. D. Maynard, “Don't Define Nanomaterials,” Nature 475, no. 7354 ( 2011 ): 31, available at < http://www.nature.com/nature/journal/v475/n7354/full/475031a.html > (last visited November 28, 2012).en_US
dc.identifier.citedreferenceA. D. Maynard and E. D. Kuempel, “Airborne Nanostructured Particles and Occupational Health,” Journal of Nanoparticle Research 7, no. 6 ( 2005 ): 587 – 614.en_US
dc.identifier.citedreferenceSee NIOSH, supra note 16; ISO, ISO TR 27628 Workplace Atmospheres—Ultrafine, Nanoparticles and Nano‐structured Aerosols —Inhalation Exposure Characterization and Assessment, 2006; D. R. Johnson, M. M. Methner, A. J. Kennedy, and J. A. Steevens, “Potential for Occupational Exposure to Engineered Carbon‐Based Nanomaterials in Environmental Laboratory Studies,” Environmental Health Perspectives 118, no. 1 (2010): 49–54; G. Ramachandran, M. Ostraat, D. E. Evans, M. M. Methner, P. O'Shaughnessy, J. D'Arcy, C. L. Geraci, E. Stevenson, A. D. Maynard, and K. Rickabaugh, “A Strategy for Assessing Workplace Exposures to Nanomaterials,” Journal of Occupational and Environmental Hygiene 8, no. 11 (2011): 673–685.en_US
dc.identifier.citedreferenceFood and Drug Administration (FDA), “Investigational New Drug Application Process,” 2011, available at < http://www.fda.gov/cder/regulatory/applications/ind_page_1.htm > (last visited November 28, 2012).en_US
dc.identifier.citedreferenceNational Institutes of Health (NIH), “Understanding Clinical Trials,” 2007 < http://clinicaltrials.gov/ct2/info/understand#Q19 > (last visited November 28, 2012); see FDA, supra note 23.en_US
dc.identifier.citedreferenceM. Kandlikar, G. Ramachandran, A. Maynard, B. Murdock, and W. Toscano, “Health Risk Assessment for Nanoparticles: A Case for Using Expert Judgment,” Journal of Nanoparticle Research 9, no. 1 ( 2007 ): 137 – 156.en_US
dc.identifier.citedreferenceW. H. de Jong and P. J. A. Borm, “Drug Delivery and Nanoparticles: Applications and Hazards,” International Journal of Nanomedicine 3, no. 2 ( 2008 ): 133 – 149.en_US
dc.identifier.citedreferenceP. H. M. Hoet, I. Bruske‐Hohlfield, and O. V. Salata, “Nanoparticles – Known and Unknown Health Risks,” Journal of Nanobiotechnology 2, no. 12 ( 2004 ): 15 pages, available at < http://www.jnanobiotechnology.com/content/pdf/1477‐3155‐2‐12.pdf > (last visited November 28, 2012); M. Geiser, B. Rothen‐Rutishauser, N. Kapp, S. Schurch, W. Kreyling, and H. Schulz, “Ultrafine Particles Cross Cellular Membranes by Nonphagocytic Mechanisms in Lungs and in Cultured Cells,” Environmental Health Perspectives 113 (2005): 1555–1560, available at < http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1310918/ > (last visited November 28, 2012); G. Oberdorster, E. Oberdorster, and J. Oberdorster, “Nanotoxicology: An Emerging Discipline Evolving for Studies of Ultrafine Particles,” Environmental Health Perspectives 113, no. 7 (2005): 823–839; M. A. Dobrovolskaia and S. E. McNeil, “Immunological Properties of Engineered Nanomaterials,” Nature Nanotechnology 2, no. 8 (2007): 469–478, available at < http://dx.doi.org/10.1038/nnano.2007.223 > (last visited November 28, 2012); D. B. Resnik and S. S. Tinkle, “Ethical Issues in Clinical Trials Involving Nanomedicine,” Contemporary Clinical Trials 28, no. 4 (2007): 433–441; G. Oberdörster, A. Elder, and A. Rinderknecht, “Nanoparticles and the Brain: Cause for Concern?” Journal of Nanoscience and Nanotechnology 9, no. 8 (2009): 4996–5007.en_US
dc.identifier.citedreferenceC. M. Sayes, A. A. Marchione, K. L. Reed, and D.B. Warheit, “Comparative Pulmonary Toxicity Assessments of C60 Water Suspensions in Rats: Few Differences in Fullerene Toxicity in vivo in Contrast to in vitro Profiles,” Nano Letters 7 ( 2007 ): 2399 – 2406; K. Donaldson, P. J. Borm, G. Oberdorster, K. E. Pinkerton, V. Stone, and C. L. Tran, “Concordance Between in vitro and in vivo Dosimetry in the Proinflammatory Effects of Low Toxicity, Low Solubility Particles: The Key Role of the Proximal Alveolar Region,” Inhalation Toxicology 20 (2008): 53–62.en_US
dc.identifier.citedreferenceA. Kroll, M. H. Pillukat, D. Hahn, J. Schnekenburger, “Current in vitro Methods in Nanoparticle Risk Assessment: Limitations and Challenges,” European Journal of Pharmaceutics and Biopharmaceutics 72 ( 2009 ): 370 – 377.en_US
dc.identifier.citedreferenceE. Kuempel, C. Geraci, and P. Schulte, “Risk Assessment Approaches and Research Needs for Nanomaterials: An Examination of Data and Information from Current Studies,” Nanotechnology: Toxicological Issues and Environmental Safety and Environmental Safety ( 2007 ): 119 – 145.en_US
dc.identifier.citedreferenceH. C. Fischer and W. C. W. Chan, “Nanotoxicity: The Growing Need For in vivo Study,” Current Opinions in Biotechnology 18 ( 2007 ): 565 – 571; M. E. McAuliffe and M. J. Perry, “Are Nanoparticles Potential Male Reproductive Toxicants? A Literature Review,” Nanotoxicology 1, no. 3 (2007): 204–210; V. Wiwanitkit, A. Sereemaspun, and R. Rojanathanes, “Effect of Gold Nanoparticles on Spermatozoa: The First World Report,” Fertility and Sterility 91, no. 1 (2009): e7‐e8, available at < http://www.sciencedirect.com/science/article/B6T6K‐4RB5BNR‐2/2/33a12feb54d3316276cbabaa2d9492b0 > (last visited November 28, 2012); A. A. Shvedova and V. E. Kagan, “The Role of Nanotoxicology in Realizing the ‘Helping without Harm’ Paradigm of Nanomedicine: Lessons from Studies of Pulmonary Effects of Single‐Walled Carbon Nanotubes,” Journal of Internal Medicine 267, no. 1 (2010): 106–18, available at < http://dx.doi.org/10.1111/j.1365‐2796.2009.02188.x > (last visited November 28, 2012).en_US
dc.identifier.citedreferenceSee Resnik and Tinkle, supra note 32.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1748-720X.2012.00714.x.pdf
Size:
232.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.